82159-09-9
82159-09-9
Chemical Structure
Epalrestat
Synonym(s): ONO2235
- CAS 番号: 82159-09-9
- Formula:C15H13NO3S2
- Molecular Weight:319.40
IUPAC Name: 2-((Z)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid
InChIKey: CHNUOJQWGUIOLD-NFZZJPOKSA-N
SMILES: O=C(O)CN(C/1=O)C(SC1=C/C(C)=C/C2=CC=CC=C2)=S
Biological Activity: Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Epalrestat | 99.62% | Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Epalrestat (Standard) | 98.59% | Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Epalrestat-d5 | Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BH3I-1 | 98.0% | BH3I-1 is a Bcl-2 family antagonist, which inhibits the binding of the Bak BH3 peptide to Bcl-xL with a Ki of 2.4±0.2 μM in FP assay. BH3I-1 has a Kd of 5.3 μM against the p53/MDM2 pair. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ML 145 (Standard) | ML 145 (Standard) is the analytical standard of ML 145 (HY-107536). This product is intended for research and analytical applications. ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM). ML 145 has no significant activity for GPR35 at either rodent ortholog. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BTR-1 | 99.96% | BTR-1 is an active anti-cancer agent, causes S phase arrest, and affects DNA replication in leukemic cells. BTR-1 activates apoptosis and induces cell death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PFM01 | 99.91% | PFM01, N-alkylated Mirin derivative, is a MRE11 endonuclease inhibitor. PFM01 can regulate double-strand break repair (DSBR) by nonhomologous end-joining (NHEJ) versus homologous recombination (HR). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
iCRT-5 | 99.1% | iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
InhA-IN-5 | InhA-IN-5 (compound 1) is a potent Mycobacterial tuberculosis (Mtb) trans-2-enoyl-acyl carrier protein reductase (InhA) inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DHDPS-IN-1 | DHDPS-IN-1 (compound 8) is a DHDPS inhibitor (IC50: 39 μM). DHDPS-IN-1 can be used in the area of antibacterial and herbicidal. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VHR-IN-3 | VHR-IN-3 (Compound 1) is a selective vaccinia H1-related (VHR) phosphatase inhibitor with a Ki of 0.81 μM. VHR-IN-3 mimics the phosphate group through the sulfonic acid group and competitively binds to the catalytic active center of VHR. VHR-IN-3 can be used for the research of cervical cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pin1 modulator 1 | 96.26% | Pin1 modulator 1 (compound IIb-219) is a modulator that specifically targets β-Catenin and inhibits the Wnt pathway. Pin1 modulator 1 can be used in the study of Wnt-mediated related diseases, such as cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55. [Content Brief]
- [2]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64. [Content Brief]
- [3]. Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72. [Content Brief]
